Search Results
Dec 10, 2025, 17:31 ET Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
treated metastatic pancreatic ductal adenocarcinoma (PDAC), with results anticipated in 2026.BioNTech/Genentech's BNT122, an individualized mRNA-based cancer vaccine developed in collaboration with Genentech, aims to generate neoantigen-specific immune responses. It is being tested in a Phase
More news about: DelveInsight Business Research, LLP
Dec 10, 2025, 08:00 ET Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma
patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens. The unique double-loading approach,
More news about: Diakonos Oncology
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools
More news about: Equity Insider
Dec 09, 2025, 10:20 ET Immunostimulant Market to Reach $288.82 billion, Globally, by 2034 at 9.9% CAGR: Allied Market Research
immunostimulant use globally.The market presents substantial opportunities as well. First, advancements in next-generation vaccines including mRNA-based, vector-based, and peptide vaccines are revolutionizing preventive medicine.These platforms offer rapid development cycles, strong efficacy
More news about: Allied Market Research
Dec 09, 2025, 08:00 ET CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy
trial evaluating MT-303. The study is assessing MT-303, an investigational in vivo GPC3-targeted CAR therapy delivered by the company's proprietary mRNA-LNP platform, in combination with atezolizumab and bevacizumab, the current global standard-of-care regimen for frontline HCC.
More news about: CREATE Medicines, Inc.
Dec 09, 2025, 08:00 ET Vincere Cancer Center Begins Recruitment for Clinical Studies of Pioneering Breast Cancer Screen for Women at High Risk
US cancer center partners with Syantra Inc. for further testing of Onco-ID Breast, a whole blood mRNA test for hyper-early cancer detectionCALGARY, AB, Dec. 9, 2025 /PRNewswire/ - Syantra, Inc., a biotechnology company
More news about: Syantra Inc.
Dec 08, 2025, 05:35 ET Exosomes Market Led by North America with 53% Revenue Share and Global Market Size Set to Surpass USD 2B by 2030, Says Mordor Intelligence
Spectrometry By Biomolecule Type Non-coding RNA (miRNA, lncRNA)Proteins & PeptidesLipidsmRNADNA FragmentsBy Application Diagnostics Cancer Neuro-degenerative
More news about: Mordor Intelligence Private Limited
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based
More news about: Orna Therapeutics
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics,
More news about: Vivacta Biotechnology Co., Ltd.
Dec 04, 2025, 15:17 ET AlidaBio Introduces the EpiPlex™ Duo-Mod™ Service for Concurrent m6A and Inosine Mapping with Integrated RNA Expression Profiling
AlidaBio's EpiPlex assay, and it appears to excel at both."The EpiPlex Duo-Mod Service supports m6A and inosine mapping from as little as 20 ng mRNA or 250 ng total RNA and accepts human, mouse, and rat samples, with additional species available upon request. AlidaBio performs the complete workflow,
More news about: Alida Biosciences
Dec 04, 2025, 10:01 ET Cleanroom Technologies Market Surges Toward US$10.58 Billion by 2031, Driven by Semiconductor Expansion and Biopharma Sterile Manufacturing
as the U.S., Japan, South Korea, Taiwan, and the EU expanded chip fabrication programs, while pharmaceutical companies scaled up sterile injectables, mRNA production, and gene therapy fill-finish operations.According to DataM Intelligence, consumables and equipment segments both expanded
More news about: DataM Intelligence 4 Market Research LLP
Dec 04, 2025, 07:00 ET Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America
existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported mRNA or srRNA
More news about: Replicate Bioscience
Dec 03, 2025, 21:01 ET Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFxTM (a direct CAR-function-based
More news about: Nona Biosciences
Dec 03, 2025, 08:30 ET Unlocking mRNA Performance: How Sequence Engineering and GMP Integration Accelerate Therapeutic Success, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into how mRNA performance can be strengthened through sequence design and GMP-aligned development strategies. Attendees will learn how codon optimization and UTR design influence IVT efficiency, translational output, mRNA stability and manufacturability. The featured
More news about: Xtalks
Dec 03, 2025, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for December 2025
Streamline Batch TestingDec 8 - Using Acceleration Levers to Expedite Late Phase CMC Programs for Therapeutic ProteinsDec 16 - Unlocking mRNA Performance: How Sequence Engineering and GMP Integration Accelerate Therapeutic SuccessDec 17 - Overcoming Pharmaceutical Supply Chain Risks
More news about: Xtalks
Dec 02, 2025, 11:34 ET Xtalks Announces its Life Science Webinar Calendar for December 2025
Streamline Batch TestingDec 8 - Using Acceleration Levers to Expedite Late Phase CMC Programs for Therapeutic ProteinsDec 16 - Unlocking mRNA Performance: How Sequence Engineering and GMP Integration Accelerate Therapeutic SuccessDec 17 - Overcoming Pharmaceutical Supply Chain Risks
More news about: Xtalks
Dec 02, 2025, 09:00 ET TQ Therapeutics GmbH Enters into Technology Access Agreement with Kytopen
and chemical forces to rapidly engineer hundreds of billions of healthy cells in minutes—the companies aim to advance a new generation of autologous mRNA T-cell therapies designed to revolutionize treatment across multiple disease areas.Through TAP, TQ Therapeutics will receive comprehensive proof-of-concept
More news about: Kytopen
Dec 01, 2025, 10:01 ET Respiratory Syncytial Virus Market to Reach USD 4.54 Billion by 2033 as Global Uptake of Next-Generation Vaccines & Monoclonal Antibodies Accelerates
year.Moderna, Inc.2023 Revenue: USD 6.8 billionmRNA Vaccine Portfolio Contribution: 95% of total revenueDeveloping mRNA-based RSV vaccines with multi-strain immunization potential.AstraZeneca plc2023
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 10:01 ET Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
Commercial scaling of gene therapies for hemoglobinopathies, neuromuscular disorders, and inherited retinal diseasesRise of mRNA & ASO precision medicines targeting ultra-rare genetic variantsDisease-modifying therapies for neurological & metabolic
More news about: DataM Intelligence 4 Market Research LLP
Nov 25, 2025, 11:00 ET Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
and expertise to deliver life-sciences projects from A to Z. The integration supports a growing European life-sciences market shaped by trends such as mRNA platforms, cell and gene therapies, supply-chain resilience, and rising sustainability requirements. In this environment, speed to qualified capacity
More news about: Exyte
Nov 25, 2025, 05:00 ET Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
and expertise to deliver life-sciences projects from A to Z. The integration supports a growing European life-sciences market shaped by trends such as mRNA platforms, cell and gene therapies, supply-chain resilience, and rising sustainability requirements. In this environment, speed to qualified capacity
More news about: Exyte
Nov 25, 2025, 05:00 ET Exyte schließt Integration von Pharmaplan ab: A-Z Projektausführung von GMP-Anlagen
durchgängig von A bis Z umzusetzen. Die Integration von Pharmaplan unterstützt einen wachsenden europäischen Life-Sciences-Markt, der von Trends wie mRNA-Plattformen, Zell- und Gentherapien, resilienteren Lieferketten und steigenden Nachhaltigkeitsanforderungen geprägt ist. In diesem Umfeld ist die schnelle
More news about: Exyte
Nov 25, 2025, 05:00 ET Exyte rondt integratie van Pharmaplan af: uitvoering van A tot Z in GMP-faciliteiten
biowetenschappen van A tot Z te leveren. De integratie ondersteunt een groeiende Europese markt in biowetenschappen die gevormd wordt door trends zoals mRNA-platformen, cel- en gentherapieën, veerkracht van de toeleveringsketen en toenemende duurzaamheidseisen. In deze context is de snelheid om gekwalificeerde
More news about: Exyte
Nov 25, 2025, 05:00 ET Exyte completa l'integrazione con Pharmaplan: esecuzione dalla A alla Z in strutture GMP
progetti di scienze della vita dalla A alla Z. L'integrazione supporta un mercato europeo life science in crescita, plasmato da tendenze quali piattaforme mRNA, terapie cellulari e geniche, resilienza della catena di approvvigionamento e requisiti di sostenibilità sempre più complessi. In questo contesto, la
More news about: Exyte
Nov 21, 2025, 17:32 ET Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
RNA level to control diseases at their source.Moderated by Dr. Julen Oyarzabal, CSO of Syngoi Technologies SL, the session "Gene Therapy and mRNA Therapeutics" brought together experts from both academia and industry: Dr. Sergio Linares Fernández, Unit Head of RNA Science Automation at Sanofi,
More news about: GenScript Biotech Corporation